Pre Congress Webinar Series
HUPO ReConnect 2021 kicked off with a series of live webinars which took place on August 16 and October 18. The very best of proteomics research were presented as a prelude to the main Congress sessions. The webinars comprised presentations with dedicated time for your questions and interactions with the speakers and moderator/chair. This exciting pre-congress program is complimentary and you can still register to watch the on-demand recordings until November 19.
Date: October 18, 2021
Title: Real-World Precision Medicine: Proteogenomics to Accelerate Drug Development and Patient Care (90 Minutes)
Time: 08:00 PDT (UTC-7), 11:00 EDT (UTC-4), 15:00 UTC, 17:00 CEST (UTC+2), 01:00 AET (UTC+10)(October 19)
To check your time zone, please click here.
Chair: Henry Rodriguez, USA
Co-chair: Yu-Ju Chen, Taiwan
Speaker: Matthew Ellis, USA – New Prospects for Killing ER+ Breast Cancer (Micro-scale Proteogenomics)
Speaker: Amanda Paulovich, USA – Building New Clinical Solutions for Precision Oncology via Proteogenomics
Speaker: Albert Sickmann, Germany – Proteogenomics/Proteomics: Complementing Precision Medicine with Phenotypic Data
Ever since the announcement of the Precision Medicine Initiative, there have been increasing efforts to identify and understand the basis of cancer using high-throughput technologies and the development of specialized treatments for specific subtypes of cancer, based on molecular evidence. Clinical proteogenomics is an exciting opportunity to complement the gene testing-centric clinical community for precision medicine. However, translating proteomic measurements to real-world patient care requires synergy of multiple requirements: meaningful and actionable molecular characterization, clinical and analytical validation, defining diagnosis values, and meeting regulatory compliance.
This HUPO session showcases clinical researchers discussing their stories and strategies to move proteomics towards better patient/clinical care. During this interactive broadcast, learn about the insight of three stories:
- Microscaled proteogenomics technology for predicting response of triple negative breast cancer
- Development of robust targeted platforms for clinical laboratory tests, drug development, and clinical trials
New Prospects for Killing ER+ Breast Cancer (Micro-scale Proteogenomics)
- Speaker: Matthew Ellis, MB., BChir., Ph.D., FRCP https://www.bcm.edu/people-search/matthew-ellis-21089
- Overall: Dr. Ellis will discuss how microscaled proteogenomics is applied to biopsies from triple negative breast cancer patients undergoing neoadjuvant carboplatin/docetaxel, revealing a wealth of biological features associated with chemotherapy resistance beyond immune response markers.
- Story: https://proteomics.cancer.gov/news_and_announcements/micro-scaled-method-holds-promise-improved-cancer-diagnostic-platform
- Publication: https://www.nature.com/articles/s41467-020-14381-2
Building New Clinical Solutions for Precision Oncology via Proteogenomics
- Speaker: Amanda Paulovich, MD, PhD https://www.fredhutch.org/en/faculty-lab-directory/paulovich-amanda.html
- Overview: Dr Paulovich will discuss the added value of proteogenomics to the current genome-driven approach to precision oncology, and summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into clinical trials and the clinical laboratory
- Story: https://proteomics.cancer.gov/news_and_announcements/cptac-contributes-identification-novel-pharmacodynamic-biomarker-clinical and https://www.hupo.org/HUPOST/9273146
- Publication: https://www.nature.com/articles/s41416-018-0286-4
Proteogenomics/Proteomics: Complementing Precision Medicine with Phenotypic Data
- Speaker: Albert Sickmann, PhD https://www.isas.de/en/institut/abteilungen/personen/albert-sickmann/
- Overview: Dr. Sickmann will present examples for proteogenomic phenotyping of KRASwildtype and KRASG12V in CRC liver metastases. Several peptides identified in this study represent a number of predicted somatic mutations, including KRASG12V. A tailor made multiplexed parallel reaction monitoring (PRM) assay was used for precise quantification of mutation rates on the protein level. Such PRM-based tumor-phenotyping might improve patient stratification in the future. He will discuss the impact of regulatory compliance (from a central European perspective) for the translation of proteomics based biomarkers towards clinical use.
- Publication: https://doi.org/10.3390/cancers11121907
Date: August 16, 2021
Title: Metaproteomics
Time: 05:00 PDT (UTC-7), 08:00 EDT (UTC-4), 12:00 UTC, 14:00 CEST (UTC+2), 22:00 AEST (UTC+10)
Co-Chair: Tim Van Den Bossche
Co-Chair: Jean Armengaud
Metaproteomics from Bench to The Clinic, Daniel Figeys
Analysis of Functions Expressed by Microbiomes Using Metaproteomics, Pratik Jagtap
Learn about our speakers and chairs
Matthew Ellis
As Director for the Lester and Sue Smith Breast Center at Baylor College of Medicine I coordinate an interdisciplinary team of oncologists, pathologists, epidemiologists, basic scientists and statisticians focused on improving the prevention, detection and treatment of breast cancer.
Amanda Paulovich
Dr. Paulovich completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Oncology at Dana-Farber Cancer Institute. She completed her PhD. training in genetics with Dr. Lee Hartwell at the University of Washington and postdoctoral training in genomics at MIT.
Daniel Figeys
Daniel is a Professor and a Distinguished Research Chair in the Department of Biochemistry, Microbiology, and Immunology at the University of Ottawa. He is the co-founding director of the Shanghai Institute of Materia Medica-University of Ottawa Joint Center in Systems and Personalized Pharmacology.
Jean Armengaud
Jean Armengaud is Chief Deputy of the laboratory of Innovative technologies for Detection and Diagnostics located near Avignon in France. He is also Director of the ProGénoMIX platform, specialized in proteogenomics and metaproteomics. He received his PhD in Biochemistry at the University of Grenoble.
Pratik Jagtap
Pratik Jagtap is a Research Assistant Professor at the Department of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota in Minneapolis, Minnesota, He received his Ph.D. degree in 2000 at the Center for Cellular and Molecular Biology, Hyderabad (India). His current research interests include developing workflows for the analysis of complex data.
Tim Van Den Boscche
Tim Van Den Bossche is working as PhD researcher in the CompOmics lab of prof. Lennart Martens in the field of microbial community proteomics, commonly known as metaproteomics. Here, he led the first-ever, community-driven, multi-site experiment that compared the effects of different state-of-the-art metaproteomics analysis pipelines (wet-lab and computational).
Yu-Ju Chen
Yu-Ju Chen received Ph.D. degree in physical chemistry from Iowa State University. After postdoctoral work at Ames Laboratory, USA, and National Tsing Hua University, Dr. Chen joined the Institute of Chemistry of Academia Sinica and is currently a Distinguished Research Fellow. She is also the President of Human Proteome Organization, past Vice President of Asia Oceana Human Proteome Organization, past President of Taiwan Proteomics Society and Taiwan Society for Mass Spectrometry.
Sponsored Content
